Nasal T cell lymphoma: a rare entity.
Nasal type of Natural Killer (NK)/T cell lymphoma manifests in the nasal cavity. Approximately 95% of them are associated with EBV(Ebstein Barr Virus) with a strong predilection for the Asian population. It has certain systemic and localized symptoms which aid in diagnosis of the condition. However, the histological criteria is pivotal in confirming the diagnosis as well as aiding in confirming the association of EBV. Nasal type of NK/T cell lymphoma has a guarded prognosis. Treatment plan include radiotherapy with concurrent chemotherapy. Despite all this, the 5-year survival rate ranges from 15-75%. A 35 years old male presented with an ulcerative nasal lesion. Diagnosed as nasal type of NK/T cell lymphoma via a tissue biopsy, it was managed by chemo-radiotherapy leading to complete resolution of symptoms and disease free on his follow-up 6 months later.
Department of Otolaryngology, Head and Neck Surgery, The Aga Khan University Hospital, Karachi.
Maliha
M
Kazi
Department of Otolaryngology, Head and Neck Surgery, The Aga Khan University Hospital, Karachi.
Mubasher
M
Ikram
Department of ENT- Head and Neck Surgery, Jinnah Medical and Dental College, Karachi.
Montasir
M
Junaid
D000328:Adult; D000951:Antigens, Neoplasm / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001706:Biopsy; D019002:CD56 Antigen / Q000032:analysis*; D059248:Chemoradiotherapy; D003520:Cyclophosphamide; D004317:Doxorubicin; D006801:Humans; D007694:Killer Cells, Natural / Q000473:pathology*; D016399:Lymphoma, T-Cell / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D008297:Male; D009296:Nasal Cavity / Q000473:pathology; D009669:Nose Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D011241:Prednisone; D016896:Treatment Outcome; D014750:Vincristine
D000951:Antigens, Neoplasm; D019002:CD56 Antigen; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone